Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours.
In order to evaluate the significance of adhesion molecules expressed on melanocytic tumours for progression and prognosis in vivo, we studied integrin expression (VLA-1 to VLA-6, CD18, CD51, CD61) on 10 naevi, 40 primary malignant melanomas, and 11 metastases by immunohistology using the APAAP technique. Evaluation was done by grouping the percentage of positive tumour cells in six categories. Statistical analysis (Wilcoxon rank test, Scheffe test) revealed significant differences in the expression of VLA-1 (P < 0.0001), VLA-2 (P = 0.0001), VLA-5 (P = 0.0093), VLA-6 (P = 0.0232), and CD61 (P = 0.0002) between naevi and primary melanomas. Comparing primary melanomas with metastases, a statistically significant decrease in the expression of VLA-1, VLA-2, and VLA-6 was detectable, as well as a significant increase in VLA-4 and VLA-5. There was no correlation between integrin expression and tumour type (superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma), regression and ulceration. Changes of VLA-1, VLA-4, and VLA-6 expression correlated with the tumour thickness of the primary melanoma, but only VLA-4 and VLA-6 expression on primary melanomas correlated significantly with the development of metastases (P = 0.024 and P = 0.001). These changes of integrin expression during tumour progression particularly, the data showing an increase of VLA-4, and a decrease of VLA-6 expression support the concept that integrins are a new additional set of prognostic markers which indicate predisposition to the development of metastases.
Schadendorf
D
D
Department of Dermatology, University Hospital Rudolf Virchow, FU Berlin, Germany.
Gawlik
C
C
Haney
U
U
Ostmeier
H
H
Suter
L
L
Czarnetzki
B M
BM
D015703:Antigens, CD / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis*; D018821:CD18 Antigens; D006801:Humans; D007150:Immunohistochemistry; D016023:Integrins / Q000378:metabolism*; D008545:Melanoma / Q000378:metabolism*; D009362:Neoplasm Metastasis; D009506:Nevus / Q000378:metabolism; D011379:Prognosis; D016029:Receptors, Very Late Antigen / Q000032:analysis
D015703:Antigens, CD; D014408:Biomarkers, Tumor; D018821:CD18 Antigens; D016023:Integrins; D016029:Receptors, Very Late Antigen